NEURANA PHARMACEUTICALS
Neurana Pharmaceuticals is a biotechnology company that is currently developing a novel treatment for acute muscle spasms. The company was founded in 2013 and headquartered in California, United States.
NEURANA PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2013-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.neuranapharma.com
Total Employee:
1+
Status:
Active
Contact:
+1 858-732-0700
Email Addresses:
[email protected]
Total Funding:
60 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Google GStatic Google Static Content Google Cloud
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Investors List
MagnaSci Ventures
MagnaSci Ventures investment in Series A - Neurana Pharmaceuticals
Longitude Capital
Longitude Capital investment in Series A - Neurana Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series A - Neurana Pharmaceuticals
H.I.G. BioHealth Partners
H.I.G. BioHealth Partners investment in Series A - Neurana Pharmaceuticals
New Leaf Venture Partners
New Leaf Venture Partners investment in Series A - Neurana Pharmaceuticals
Official Site Inspections
http://www.neuranapharma.com
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neurana Pharmaceuticals"
Neurana Pharmaceuticals - Crunchbase Company Profile & Funding
Neurana Pharmaceuticals is a biotechnology company that is currently developing a novel treatment for acute muscle spasms. The company was founded in 2013 and headquartered in …See details»
Neurana Pharmaceuticals Company Profile | Management and
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the …See details»
Overview, News & Similar companies - ZoomInfo.com
Nov 28, 2021 · Neurana Pharmaceuticals contact info: Phone number: (858) 756-2480 Website: www.neuranapharma.com What does Neurana Pharmaceuticals do? Neurana …See details»
Neurana Pharmaceuticals - PitchBook
Operator of a specialty pharmaceutical agency intended to treat neuromuscular conditions. The company's agency offers a novel skeletal muscle relaxant for the treatment of acute, painful …See details»
www.neuranapharma.com
Www.neuranapharma.comSee details»
Neurana Pharmaceuticals - Craft
Neurana Pharmaceuticals is a company developing a treatment for central nervous system (CNS) diseases and disorders. Its product Tolperisone is a non-opioid medication for acute muscle …See details»
Neurana Pharmaceuticals Seeks Strategic Alternatives Following …
Mar 22, 2022 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals, Inc. | Insights
Jun 5, 2018 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 …
SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, to...See details»
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3
Jun 7, 2021 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
neuranapharma.com
Neuranapharma.comSee details»
Neurana Pharmaceuticals Seeks Strategic Alternatives Following …
Mar 22, 2022 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals to Present at American Society of ...
Jun 25, 2021 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 …
Nov 29, 2021 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, …
Jun 7, 2021 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals to Present at American Society of ...
Jun 25, 2021 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful …See details»
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, …
SAN DIEGO, June 7, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, tod...See details»
Neurana Pharmaceuticals Announces First Patient Enrolled in CNS …
Jun 8, 2020 · Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, including …See details»
Neurana Pharmaceuticals Announces Top-Line Results from
SAN DIEGO, Dec. 8, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top …See details»
Neurana Pharmaceuticals Announces Top-Line Results from …
SAN DIEGO, Dec. 8, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line …See details»